UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 71

Sortiert nach

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

The New England journal of medicine, 2017-07, Vol.377 (4), p.338-351

2017

Volltextzugriff (PDF)

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

The lancet oncology, 2023-03, Vol.24 (3), p.213-227

2023

Volltextzugriff (PDF)

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

The Lancet (British edition), 2018-12, Vol.392 (10162), p.2353-2366

2018

Volltextzugriff (PDF)

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)

International journal of cancer, 2022-08, Vol.151 (3), p.422-434

2022

Volltextzugriff (PDF)

Dry Eye Disease and Microbial Keratitis: Is There a Connection?

The ocular surface, 2013-04, Vol.11 (2), p.75-92

2013

Volltextzugriff (PDF)

Interleukin-1 receptor-1-deficient mice show attenuated production of ocular surface inflammatory cytokines in experimental dry eye

Cornea, 2008-08, Vol.27 (7), p.811

2008

Volltextzugriff (PDF)

In Vitro Activity of Human β-Defensin 2 against Pseudomonas aeruginosa in the Presence of Tear Fluid

Antimicrobial Agents and Chemotherapy, 2007-11, Vol.51 (11), p.3853-3860

2007

Volltextzugriff (PDF)

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

European urology oncology, 2018-12, Vol.1 (6), p.449-458

2018

Volltextzugriff (PDF)

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

The Lancet (British edition), 2022-01, Vol.399 (10323), p.447-460

2022

Volltextzugriff (PDF)

The effect of interleukin-1 on cytokine gene expression by human corneal epithelial cells

Experimental eye research, 2005-02, Vol.80 (2), p.175-183

2005

Volltextzugriff (PDF)

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial

PLoS medicine, 2022-06, Vol.19 (6), p.e1003998

2022

Volltextzugriff (PDF)

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

The lancet oncology, 2023-05, Vol.24 (5), p.443-456

2023

Volltextzugriff (PDF)

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study

Nature genetics, 2009-10, Vol.41 (10), p.1116-1121

2009

Volltextzugriff (PDF)

Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial

British journal of cancer, 2023-09, Vol.129 (4), p.706-720

2023

Volltextzugriff (PDF)

Advancements in anti-inflammatory therapy for dry eye syndrome

Optometry (Saint Louis, Mo.), 2009-10, Vol.80 (10), p.555-566

2009

Volltextzugriff (PDF)

Ocular mucin gene expression levels as biomarkers for the diagnosis of dry eye syndrome

Investigative ophthalmology & visual science, 2011-10, Vol.52 (11), p.8363-8369

2011

Volltextzugriff (PDF)

Thyroid cancer susceptibility polymorphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24

Journal of medical genetics, 2012-03, Vol.49 (3), p.158-163

2012

Volltextzugriff (PDF)

Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4561-4561

2018

Volltextzugriff (PDF)

Prospective, multinational, observational study of real-world treatment outcomes with pazopanib in patients with advanced or metastatic renal cell carcinoma (PRINCIPAL study)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4574-4574

2018

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(63)

Publikationsform

Sprache

Englisch
(71)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial

Dry Eye Disease and Microbial Keratitis: Is There a Connection?

Interleukin-1 receptor-1-deficient mice show attenuated production of ocular surface inflammatory cytokines in experimental dry eye

In Vitro Activity of Human β-Defensin 2 against Pseudomonas aeruginosa in the Presence of Tear Fluid

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

The effect of interleukin-1 on cytokine gene expression by human corneal epithelial cells

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study

Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial

Multiple loci on 8q24 associated with prostate cancer susceptibility

Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial

Advancements in anti-inflammatory therapy for dry eye syndrome

Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004)

Ocular mucin gene expression levels as biomarkers for the diagnosis of dry eye syndrome

Thyroid cancer susceptibility polymorphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24

Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma

Prospective, multinational, observational study of real-world treatment outcomes with pazopanib in patients with advanced or metastatic renal cell carcinoma (PRINCIPAL study)

Suchergebnisse filtern